Pyrrolo[2,3-d]pyrimidinyl, pyrrolo[2,3-b]pyrazinyl and pyrrolo[2,3-d]pyridinyl acrylamides

CPC - классификация

AA6A61A61KA61K3A61K31A61K31/A61K31/4A61K31/43A61K31/437A61K31/4375A61K31/45A61K31/452A61K31/4523A61K31/5A61K31/51A61K31/519A61PA61P1A61P1/A61P1/0A61P1/00A61P1/04A61P1/1A61P1/16A61P1/18A61P11A61P11/A61P11/0A61P11/00A61P11/06A61P11/08A61P13A61P13/A61P13/1A61P13/12A61P15A61P15/A61P15/0A61P15/08A61P17A61P17/A61P17/0A61P17/00A61P17/02A61P17/04A61P17/06A61P17/1A61P17/14A61P19A61P19/A61P19/0A61P19/02A61P19/04A61P2A61P21A61P21/A61P21/0A61P21/00A61P21/04A61P25A61P25/A61P25/0A61P25/00A61P25/08A61P25/1A61P25/14A61P25/16A61P25/18A61P25/2A61P25/22A61P25/24A61P25/28A61P27A61P27/A61P27/0A61P27/02A61P29A61P29/A61P29/0A61P29/00A61P3A61P3/A61P3/0A61P3/00A61P3/1A61P3/10A61P35A61P35/A61P35/0A61P35/00A61P35/02A61P37A61P37/A61P37/0A61P37/02A61P37/06A61P37/08A61P4A61P43A61P43/A61P43/0A61P43/00A61P5A61P5/A61P5/1A61P5/14A61P7A61P7/A61P7/0A61P7/00A61P7/04A61P7/06A61P9A61P9/A61P9/0A61P9/00A61P9/1A61P9/10CC0C07C07DC07D4C07D47C07D471C07D471/C07D471/0C07D471/04C07D471/08C07D48C07D487C07D487/C07D487/0C07D487/04C07D487/1C07D487/10C07D49C07D498C07D498/C07D498/0C07D498/04C07D5C07D51C07D519C07D519/C07D519/0C07D519/00

IPC - классификация

AA6A61A61KA61K3A61K31A61K31/A61K31/4A61K31/45A61K31/452A61K31/4523A61PA61P1A61P1/A61P1/1A61P1/16A61P2A61P29A61P29/A61P29/0A61P29/00A61P4A61P43A61P43/A61P43/0A61P43/00CC0C07C07DC07D4C07D47C07D471C07D471/C07D471/0C07D471/04C07D471/08C07D48C07D487C07D487/C07D487/0C07D487/04C07D487/1C07D487/10C07D49C07D498C07D498/C07D498/0C07D498/04

Цитирование НПИ

Cochi et al, “Access to Optically Active 3-Aminopiperidines by Ring Expansion of Prolinols: Thermodynamic versus Kinetic Control”, European Journal of Organic Chemistry 10:2023-2040 (2012).
Cochi et al, “Access to Optically Active 3-Azido- and 3-Aminopiperidine Derivatives by Enantioselective Ring Expansion of Prolinols”, Organic Letters 13(16):4442-4445 (2011).
Hill, R.J., et al., “Discovery of a highly potent, selective, reversible covalent inhibitor of JAK3”, Arthritis and Rheumatism. Conference: Annual Scientific Meeting of the American College of Rheumatology and Association of Rheumatology Health Professionals 2012, Washington, DC, United States, Conference Publication: (var.pagings). 64 (pp. S982), 2012. Date of Publication: Oct. 2012. Abstract.
Jarganas et al, “Jak2 Is Essential for Signaling through a Variety of Cytokine Receptors”, Cell 93:385-395 (1998).
Joss, J., et al., “Characterization of ABT-494, A Second Generation Jak 1 Selective Inhibitor”, 78th ACR/ARHP Annual Scientific Meeting, Nov. 14-19, 2014, Boston, Massachusetts, Abbvie Bioresearch Center, Oct. 20, 2014, Abstract.
Kisseleva et al, “Signaling through the JAK/STAT pathway, recent advances and future challenges”, Gene 285:1-24 (2002).
Murray, “The JAK-STAT Signaling Pathway: Input and Output Integration”, The Journal of Immunology 178:2623-2629 (2007).
Neubauer et al, “Jak2 Deficiency Defines an Essential Developmental Checkpoint in Definitive Hematopoiesis”, Cell 93:397-409 (1998).
Norman, P., “Highly selective Janus kinase 3 inhibitors based on a pyrrolo [2,3-d]pyrimidine scaffold: evaluation of WO2013085802”, Expert Opin, Ther. Patents, 24(1):121-125 (2014).
O'Shea et al, “Cytokine Signaling in 2002: New Surprises in the Jak/Stat Pathway”, Cell 109:S121-S131 (2002).
Padilla et al, “Pyrrolopyrazines as Selective Spleen Tyrosine Kinase Inhibitors”, Journal of Medicinal Chemistry 56(4):1677-1692 (2013).
Wrobleski, S.T., et al., “Advances in the Discovery of Small Molecule JAK3 Inhibitors”, Annual Reports in Medicinal Chemistry, 44:247-264 (2009).
Wu et al. FDA-approved small-molecule kinase inhibitors. Trends in Pharmacological Sciences, 2015, 36, 422-439.
Yamaoka et al, “The Janus kinases (Jaks)”, Genome Biology 5(12):Article 253 (2004).